NIH R01 · 2024
Project Summary/abstract Triple negative breast cancer (TNBC) is the most aggressive breast cancer subtype and poses a clinical challenge due to the lack of tools to predict patients who are at risk of death due to disease. TNBCs subtypes were presumed to be a step forward, however, recent randomized clinical trials have failed to document differential impact of therapy within TNBC subtypes. Immunotherapies will benefit a small subgroup (~7 out of 100 women) of TNBC patients, but are associated with 15-30% increase in grade 3 immune toxicities. Currently, all patients with TNBCs are offered chemotherapy-based regimens either after surgery (70%) or less often (~30%) before surgery…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.